Filing Details
- Accession Number:
- 0001209191-22-017150
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-08 16:59:13
- Reporting Period:
- 2022-03-04
- Accepted Time:
- 2022-03-08 16:59:13
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1805890 | Fusion Pharmaceuticals Inc. | FUSN | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1813574 | John Valliant | C/O Fusion Pharmaceuticals, Inc. 2 International Place, Suite 2310 Boston MA 02110 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2022-03-04 | 8,400 | $7.32 | 396,390 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-03-07 | 3,100 | $6.99 | 393,290 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-03-08 | 3,004 | $6.92 | 390,286 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.15 to $7.53 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.95 to $7.16 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.83 to $7.07 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
Billionaire Hedge Funds
